Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQMRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nelson v. Maravai LifeSciences Holdings, Inc., et al., Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) and reminds investors of the May 5, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nelson v. Maravai LifeSciences Holdings, Inc., et al., Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) on behalf of Maravai stockholders. Our investigation concerns whether Maravai has violated the federal securities laws and/or engaged in other unlawful business practices.

Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQMRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) investors concerning the Company’s possible violations of the federal securities laws.

Shares of Maravai LifeSciences Holdings, Inc. (“Maravai LifeSciences”) plunged over 21% in intraday trading on Tuesday, February 25, 2025, after the company disclosed it would be delaying its 2024 earnings release. The company delayed the earning release and investor call, stating that it needs additional time to complete an assessment of disclosure controls and internal controls over financial reporting. Gibbs Law Group is investigating a potential Maravai LifeSciences (NASDAQMRVI) Securities Class Action Lawsuit on behalf of shareholders who lost money in Maravai LifeSciences Holdings.

Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or before March 18, 2025, prior to the expiration of the automatic extension of fifteen calendar days from the original 2024 Form 10-K due date of March 3, 2025.

Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and novel technologies for quick, calculated progression through the mRNA sequence-optimization phase and into clinical testing and commercial manufacturing.

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQMRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines.

Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies.

Announces Earnings Release Date

Carl Hull to Retire as Executive Chairman

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.

MRVI earnings call for the period ending September 30, 2024.